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Abstract
Clinical biomarkers play an important role in personalized medicine in cancer clinical trials. A response adaptive trial design enables researchers to use treatment results observed from early patients to aid in treatment decisions of later patients. In
this article, we describe the mathematical steps for computing the theoretical optimal biomarker-integrated adaptive trial designs. The optimal design maximizes the
expected trial utility given any pre-specified utility function, though we focus here on
maximizing responses within a given patient horizon. We describe the performance
of the optimal design under different scenarios. Bayesian Adaptive Randomization
(BAR) is emerging as a practical approach to develop adaptive trials. We compare
the Bayesian Adaptive Randomization(BAR) and the theoretical optimum to quantify
the loss of utility in different scenarios. We conclude that BAR is nearly optimal in a
broad range of scenarios. We also compare the BAR to a frequentist play-the-winner
rule where biomarkers are integrated. Our work provides absolute benchmark for the
evaluation of trial designs in personalized medicine.

1

Introduction

Recent insight into the genetic drivers of cancer [Wood et al., 2007], the development of
drugs whose action depends specifically on the activity of these targets, and the resulting
heterogeneity of treatment responses have highlighted the need to systematically include
information on a tumor’s genetic characteristics into treatment decisions. This trend is generally referred to as ”precision” or ”personalized” cancer treatment [Savard, 2013, Schilsky,
2010]. A tremendous amount of resources is presently allocated to developing personalized
cancer medicine [Chin et al., 2011, Compton, 2007, Hamburg and Collins, 2010, La Thangue
1
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and Kerr, 2011, van’t Veer and Bernards, 2008, Walther et al., 2009]. Since the Food and
Drug Administration (FDA) approved trastuzumab [Baselga et al., 1998] in human epidermal
growth factor receptor 2 (HER2)-positive breast cancer patients, there have been development of personalized medicine for the treatment of chronic myelogenous leukemia[Druker
et al., 2001], colon cancer [Allegra et al., 2009], lung cancer [Paez et al., 2004], and others
[Gonzalez-Angulo et al., 2010, McDermott and Settleman, 2009].
The development of targeted treatments is inspiring a change in the design of clinical
trials. For instance, in the Biomarker-integrated Approaches of Targeted Therapy for Lung
cancer Elimination (BATTLE) study [Herbst et al., 2010, Kim et al., 2011, Rubin et al.,
2011], non-small cell lung cancer (NSCLC) patients had been classified into five subgroups
defined by biomarkers reflecting tumor genetics. A more complex biomarker-adaptive design,
also allowing treatments to enter and exit the trial is the I-SPY 2 [Barker et al., 2009]. The
goal of these trial is to identify the most beneficial treatment separately for each patient
subgroups.
Statistically, adaptive trial designs for cancer clinical trials have been studied extensively,
including both frequentist [Eisele, 1994, Ivanova, 2003, Wei and Durham, 1978, Zelen, 1969]
and Bayesian designs [Atkinson and Biswas, 2005, Berry and Eick, 1995, Rosner and Bekele,
2010, Thall and Wathen, 2007], although biomarkers are not often included. From a decision
theoretic perspective, we lack results on optimal trial designs integrating biomarkers. In this
paper, we fill this gap by deriving an optimal Bayesian biomarker-integrated adaptive trial
design. Our optimality goal is to maximize the number of successfully treated patients over a
given horizon, including the patients in the trial itself. Our results generalize earlier work by
[Berry and Eick, 1995]. Our optimal design assigns treatment to each patient based on their
own biomarker, and on accumulating results in the trial. At the end of the trial, patients
are assigned to their optimal treatment, potentially depending on the biomarker, for the
remainder of the horizon of interest.
Having developed the theory behind the optimal design, it is now possible to evaluate
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the efficiency of more heuristic approaches by comparing their utility to the optimum. While
the optimal design maximizes the expected trial utility, the treatment assignment at each
stage is deterministic and it imposes heavy computational burden [Powell, 2007]. Thus, a
natural comparison is with the Bayesian Adaptive Randomization (BAR) design [Thall and
Wathen, 2007], and with the frequentist play-the-winner rule. The comparison will show
that using BAR does not generally lead to a significant loss in terms of the expected trial
utility when compared to the theoretical optimum. BAR often shows higher expected trial
utility than play-the-winner rule when the patient population is stratified by biomarkers.
This comparison is the primary practical goal of this article.
In Section 2 we define the problem and provide a description of the optimal trial design.
We assume a binary response, with no delay, and a general multivariate binary biomarker
space. In section 3, we interpret how the biomarker affects the optimal expected trial utility,
using synthetic data. In section 4 we address computational and design issues.

2
2.1

Biomarker Integrated Trials
Assumptions and Notation

We assume that n patients are recruited in a clinical trial to study the effects of I treatments, labeled by i ∈ {1, ..., I}. There are K biomarkers integrated in the trial, with binary
biomarker indicators bk ’s, k = 1, ..., K. For example if the biomarkers are somatic mutations
in the tumor, bk = 1 denotes the presence of a mutation in gene k, while if bk = 0 the gene is
unaltered. Patients’ profiles can be defined by these biomarkers indicators and summarized
by the vector G = (b1 , ...bK ). There are many options for dividing patients into subgroups
according to their profiles. For example, 4 biomarkers are used in the BATTLE trial to define
biomarker groups [Zhou et al., 2008]. Using our notation, K = 4. Also b1 : EGFR mutation
or amplification, b2 : K-ras and / or B-raf mutation, b3 : VEGF and / or VEGFR expression,
b4 : RXR and / or cyclin D1 expression. In the BATTLE trial, if a patient has any profile
3
Hosted by The Berkeley Electronic Press

with b1 = 1, he/she belongs to the EGFR mutation/amplification group. Any patient with
b1 = 0, b2 = 1 is binned in a second profile with EGFR negative and a K-ras/B-raf positive
tumors, and so forth (see [Zhou et al., 2008] for the complete algorithm). A patient with
G = (0, 0, 0, 0) is assigned to the ”no mutation” group. However, this is not the only way
of defining biomarker groups. For example, if one is interested in investigating the effects
of drugs on patients with either an EGFR mutation or K-ras/B-raf mutation, then patients
with profile G = (0, 1, 0, 0) could be assigned to the same group as patients with profile
G = (1, 0, 0, 0). The optimal trial design proposed in this paper can be applied in both
situations described above, as long as biomarker groups are mutually exclusive. We denote
by j be the biomarker groups in the trial, with j ∈ {1, ..., J}.
Similarly to [Berry and Eick, 1995], we consider a patient horizon, including patients in
the trial, as well as subsequent patients who will be treated based directly on the result of
trial. The size of the patient horizon is an important element in adaptive designs [Upton
and Lee, 1976], because it controls how the design balances the two potentially competing
needs of learning the treatment effects and treating patients ethically within the trial.
We assume that the outcome of interest is binary and that it is known immediately after
treatment for each patient. Let wij be the probability of observing a success, or response
rate, for treatment i in subgroup j, ∀i, j. The goal of a clinical trial is to study the effects of
different treatments in various biomarker subgroups, to choose the most effective treatment
for each of these subgroup at the end of the trial, and to apply it for the remainder of the
patient horizon. The values of wij are the parameters of interest.
We take a Bayesian approach to quantifying uncertainty in these parameters. We use
a mixture prior, assigning a positive probability to the event that the effect of treatment i
is the same across all biomarker groups, that is that wi1 = ... = wiJ , as well as a positive
probability to the event that there are some biomarker effects. Conditional on the latter,
we define the prior distributions in the following way. The marginal priors of wij ’s are
Beta(1,1). The effects of two different treatments are independently distributed, whether
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within or across subgroups. Namely, wij is independent of wi0 j 0 , for i 6= i0 ; ∀j, j 0 . When the
effect of a treatment is allowed to vary across subgroups, it can take a different value in each
subgroup. We do not consider the possibility that the effects may be equal in some subgroups
and different in others because of the combinatorial complexity, though in practice this could
be biologically justified. Consider now the effect of treatment i across biomarker groups, we
allow for the possibility that treatment efficacy depends on biomarkers and use the following
model as the joint prior of the treatment effects. Treatment i, with prior probability πi , has
the same effect across biomarker groups. If the effects of treatment i are not equal, they are
independent and can be modeled with a multivariate uniform distribution. To summarize,
the joint prior distribution of the unknown response rates for treatment i is

P r(Wi1 ≤ wi1 , ..., WiJ ≤ wiJ ) = (1 − πi )

J
Y
j=1

J

wij + πi min{wij }
j=1

(1)

with the second term capturing the case when effects for treatment i are the same across
all biomarker groups. The hyperparameters πi , i = 1, ..., I are fixed and represent the prior
probability that the effect of treatment i depends on the biomarkers. The πi ’s can be
estimated from early phase trials or elicited from expert judgment. [Hammitt and Zhang,
2013].
In this paper, we study this specific prior in detail. However, our approach is more general,
in that the algorithm we describe can easily accommodate other prior distributions. If reliable
evidence on treatment effects is available from early phase trials, it can be summarized via
0
the prior distributions of the wij
s, relaxing on assumption of uniformity.

Let Xn denote the treatment outcome of the nth patient enrolled in the trial, and Gn the
associated marker profile. The arrival of patient n also marks the nth decision point in the
optimal allocation: an adaptive trial design d assigns patient n to one of the I treatments
based on results observed until decision point n. The notation d(n|Xn−1 , ..., X1 , Gn , ..., G1 ) =
i indicates that the design assigns patient n to treatment i after observing the treatment
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outcomes of the first n − 1 patients. The treatment assignment depends on the treatment
outcomes of the previous n − 1 patients summarized by Xn−1 , ...X1 , Gn , ..., G1 , and on the
marker profile Gn of the nth patient. The best treatment for each biomarker subgroup is
determined at the end of the trial and will be prescribed to future patients according to their
marker profiles. After the trial, all patients in the same biomarker group will receive the
same treatment.
We next define some notation that will be used in the calculation of the theoretical
optimum. After the nth patient has been assigned to a treatment and the outcome has been
observed, we use matrices M(n) and S(n) to record the accumulated information up to that
(n)

point. The entry mij , on the ith row and j th column of matrix M(n) , is the total number
(n)

of patients in subgroup j assigned to treatment i up to that time point. The entry sij ,
(n)

on the ith row and j th column of the matrix S(n) , is the number among the mij patients
who responded to the treatment. Both matrices are of size I × J. We assume that Xn ’s are
conditionally independent given Gn ’s and wij ’s. Thus, M(n) and S(n) together serve as the
sufficient statistics for the treatment effects for the data up to decision point n.
We are interested in choosing a design d from the set D of all possible biomarkerdependent patient allocations. A trial of size N is conducted following design d to study the
unknown treatment effects w = (wij )I×J , and w ∈ Ω. When the allocation is d, x ∈ X is
observed with conditional density fd (x|w), where x = (x1 , ...xn )0 . At the end of the trial,
the best treatment in each subgroup is selected and will be prescribed to future patients. We
model this by considering a group of Nh − N additional patients whose treatment decision
will be collectively affected by the information accrued during the trial. This final treatment
assignment is the last stage of the decision process and is called the ”terminal decision”. The
quantity Nh is often termed ”patient horizon” [Colton, 1963, Canner, 1970]. While d denotes
the allocation of patients to treatments during the trial, dH denotes the joint allocation of
the remaining Nh − N patients to treatment following the trial. In our work dH is allowed
to depend on the individual patient’s marker profile.
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The best treatment is defined with respect to a utility function U (d, dH , x) designed to
capture the most important goals of conducting the trial. Comparing treatment efficacy is
helpful insofar as it allows to improve treatment outcomes. Here we explicitly consider the
outcomes of all Nh patients, including the N in the trial and the subsequent Nh − N in
clinical practice. A utility function is defined as the total number of favorable treatment
outcomes:

U (d, dH , x) ==

N
X

xn

+

{z }
|n=1

inside the trial

Nh
X

xn

(2)

n=N +1

| {z }

outside the trial

This specific form of utility function has been used by several authors [Armitage, 1985,
Berry and Eick, 1995] in the design of trials not incorporating biomarkers. We will use this
utility function to illustrate the behavior of the optimal design under different biomarker
effects, and to make comparisons among trial designs.

2.2

Optimal Solution

The optimal adaptive choice of d and dH is obtained by dynamic programming [Bellman,
2003, Parmigiani and Inoue, 2009]. We begin with the optimal dH , which is computed
conditional on information X1 , ..., XN , G1 , ..., GN . The expected value of the utility in (2),
given this information, is maximized by assigning each patient to the treatment with the
highest expected success rate in his/her marker group. We denote this optimum terminal
decision by d˜H (x). Now this optimal d˜ can be computed by maximizing expected utility
Z
U(d) =

U (d, d˜H (x), x)dFd (w, x),

X,w

with respect to d.
The optimal design achieves two goals: (1) identifying the best treatment for each
biomarker group at the end of a trial, (2) maximizing the expected number of favorable
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(n)

treatment outcomes. Let Rd,d˜H [M(n) , S(n) ] denote the expected number of favorable treatment outcomes from the (n + 1)th to the Nhth patient conditional on information up to stage
(n)

n. Also, let µij be the posterior mean of wij calculated conditional on the same information,
(n)

that is µij = E[wij |Xn , ..., X1 ; Gn , ..., G1 ].
(N )
(N )
This notation can be used to write deH explicitly. For example, if µĩj = maxi (µij ),

future patients in subgroup j will be assigned to treatment ĩ. At the end of a trial following
the optimal design, the expected number of future favorable treatment outcomes is

(N )
Rd,d˜H [M(N) , S(N) ]

=

Nh
X
n=N +1

I

(N )

max(µiGn ).
i=1

where the marker profile of the nth patient, Gn , determines the biomarker subgroup.
The general steps for calculating the expected trial utility of the optimal design starts
(N )

(N )

(n)

with Rd,d˜H [M(N) , S(N) ] and µij . In a backward manner, each Rd,d˜H [M(n) , S(n) ] is calculated
(n+1)

(n)

with Rd,d˜H [M(n+1) , S(n+1) ] and µij for n = N −1, ...0. Specifically, the theoretical optimum
can be calculated with the following steps:
(N )

1. Initialize Rd,d˜H [M(N) , S(N) ] =
(n)

PNh

n=N +1

(N )

maxIi=1 (µiGn )

(n+1)

(n)

2. Update Rd,d˜H [M(n) , S(n) ] with Rd,d˜H [M(n+1) , S(n+1) ] and µij
3. Repeat the previous step for n = N − 1, ..., 0
(0)

˜ =R
4. U(d)
[M(0) , S(0) ]
d,d˜H
The updating step (Step 2) demonstrates the decision-making process of treatment selection for patients enrolled in the trial. When it is time to assign a treatment to the nth patient
(n−1)

who is in subgroup j, the probability of observing a favorable treatment outcome is µij
(n−1)

if this patient is assigned to treatment i. Let {Rd(n)=i [M(n−1) , S(n−1) ]} denote the expected
number of future favorable treatment outcomes if the nth patient is treated with treatment
(n−1)

(n−1)

i, then {Rd(n)=i [M(n−1) , S(n−1) ]} can be calculated with µij

(n)

(n)

(n)

, Rd [Md(n)=i , Sd(n)=i ] and
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(n)

(n)

Rd [Md(n)=i , S(n−1) ].
(n−1)

{Rd(n)=i [M(n−1) , S(n−1) ]}
(n−1)

= µij


(n)
Md(n)=i



=



(n)

(n−1)

(n)

(n)

× Rd [Md(n)=i , Sd(n)=i ] + (1 − µij

(n−1)

m11
..
.
..
.
..
.

(n−1)
mI1

···
..
.

···

···
.
..

(n−1)

1 + mij
.

..

···

..
···

.

···

(n−1)

m1J
..
.
..
.
..
.



(n)





 (n)

,S

 d(n)=i = 



(n−1)
mIJ

I

(n−1)

(n)

) × Rd [Md(n)=i , S(n−1) ], where,

(n−1)

s11
..
.
..
.
..
.

···
..
.

(n−1)
sI1

···

···

···
.
..

.

···

sIJ

(n−1)

1 + sij
.

..

..
···

(n−1)

s1J
..
.
..
.
..
.








(n−1)

(n−1)

Rd(n)=ĩ [M(n−1) , S(n−1) ] = max({Rd(n)=i [M(n−1) , S(n−1) ]})
i

(n−1)

and Rd˜

3
3.1

(n−1)

[M(n−1) , S(n−1) ] = Rd(n)=ĩ [M(n−1) , S(n−1) ]

Numerical Results and Comparison
Properties of the Theoretical Optimum in Two-Treatments
Comparisons

Assume that a new cancer treatment (treatment 1) is to be compared with a conventional
treatment (treatment 2). Also assume that early phase studies show that patients with
a specific biomarker mutation may respond differently to the treatments, though there is
no certainty about a difference in treatment effects. The patients can be divided into two
biomarker groups: patients with mutation and patients without mutation. Patients in the
two biomarker groups may respond differently to a same treatment. The treatment response
rate wij is the probability of observing a favorable treatment outcome for a patient in subgroup j, j = 1, 2, who is assigned to treatment i, i = 1, 2. The effects of different treatments
are independent, i.e., the response rates of the new treatment are independent of the response
rates of the conventional treatment in the two biomarker subgroups. However, the response
9
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rates of a same treatment in the two biomarker groups may either be equal, or independent
when they are not equal. In other words, the effect of a treatment in the mutation group
may or may not be different from the effect of the same treatment in the no mutation group.
These assumptions, reflecting knowledge from the early phase trials, can be summarized by
the following definition of the prior distribution of the treatment response rates, which is a
special case of (1).
wij ∼ Beta(1, 1);

wis ⊥ wi0 j 0 ,

i 6= i0 ,

∀j, j 0 ;
(3)

P r(Wi1 ≤ wi1 , Wi2 ≤ wi2 ) = (1 − πi )wi1 wi2 + πi min{wi1 , wi2 },

i = 1 or 2;

Figure 1: Model parameter influence on the theoretical optimum. Patient horizon Nh = 1000,
trial size N = 50.
Two key quantities describe a biomarker: the prevalence of mutations, P r(b = 1), and π
as defined in (3). The remainder of this section considers the theoretical optimum in different
scenarios for these quantities, throughout we assume that P r(b = 1) is known from previous
studies. Figure 1 shows the relationship between π, P r(b = 1) and the utility associated
with the theoretical optimum. We simulate 1000 times of a patient horizon Nh = 1000 and
a trial size N = 50 . For the purpose of visualization, we are showing the situations when
π1 = π2 = π. The first panel of Figure 1 illustrates how the expected utility of a trial,
10
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˜ changes with π, by fixing the mutation prevalence. Each curve corresponds to the
U(d),
expected number of favorable treatment outcomes under different biomarker effects. The
two biomarker groups are exchangeable in the model assumption. Therefore, the two curves
with P r(b = 1) = δ and P r(b = 1) = 1 − δ, δ ∈ [0, 1] are identical. The curve with
˜ is
P r(b = 1) = 0 is a horizontal line because when no patient have the mutation, and U(d)
independent of π, π is a redundant parameter in the model.
When P r(b = 1) ∈ (0, 1), the patient population is a mixture of two subgroups. The
expected utility of a trial increases with π. The monotonically increasing relationship can
be explained by considering the two extreme cases with π = 0 and π = 1. When π = 0,
the two biomarker groups are independent, and the number of positive patient responses in
the total patient horizon is the sum of the numbers in the two biomarker groups. On the
other hand, when π = 1 the treatment effects are always the same in the two subgroups,
thus it is no longer necessary to differentiate the subgroups. The patient population can
be modeled as a single group. Therefore, the comparison between these two situations is
essentially comparing a larger size trial with the juxtaposition of two smaller trials. A bigger
sample size provides more information to detect the best treatment. The two subgroups
˜ is minimized when
become more closely related as π increases. At each level of π, U(d)
P r(b = 1) = 0.5. When the subgroups are getting more balanced, the joint ability to find
the best treatment in the two subgroups is the smallest.
The second panel of Figure 1 shows the expected trial utility as we vary the prevalence
of mutation with fixed π. Because the two subgroups are exchangeable, we plot the results
over the range P r(b = 1) ∈ [0, 0.5]. Had the results been plotted over P r(b = 1) ∈ [0, 1],
the curves would be symmetric about P r(b = 1) = 0.5. When π = 1, the biomarker is
known not to modify the treatment effects. The two subgroups can thus be combined and
considered as a single group. Then the expected utility of the trial does not change with
P r(b = 1), because the total sample size is fixed. Therefore, the curve corresponding to
this situation is a horizontal line and is above other curves corresponding to situations when
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the biomarker mutation modifies treatment outcomes. When π < 1, the expected number
of favorable treatment outcomes is negatively correlated with the biomarker prevalence, but
this dependence is very weak for prevalence larger than 10%.

3.2

Comparison of Bayesian Adaptive Randomization and the
Theoretical Optimum

Bayesian Adaptive Randomization (BAR) is emerging as a practical approach to develop
adaptive designs, and is computationally far more efficient than dynamic programming.
Here we explore the extent to which BAR can achieve expected utility close to that of the
optimal solution. To this end, we extend the approach by [Thall and Wathen, 2007] so that
it can be applied to trials incorporating biomarkers. When there are two treatments and
one biomarker, BAR assigns treatment 2 to the nth patient who belongs to biomarker group
(t)

j with probability rj , and
(n)

rj

=

[P r(n) (w1j < w2j )]c
[P r(n) (w1j < w2j )]c + [P r(n) (w1j > w2j )]c

where P r(n+1) (w1j < w2j ) = P r(w1j < w2j |Xn , ..., X1 , Gn , ..., G1 ) is the posterior probability
that treatment 2 is the better treatment for patients in subgroup j. With the same priors
defined in section 2. We follow [Thall and Wathen, 2007] for the choice of tuning parameter
c.
While it is relatively easy to obtain an unbiased estimator of the prevalence of mutations
in the patient population, it is often hard to choose π. In both designs, estimates of π are
required to specify a design, and π needs to be elicited using the best knowledge. In this
subsection, we will show the comparisons between the theoretical optimum and BAR in two
types of simulations: first we generate treatment effects from the prior used for designing the
trial; next we generate treatment effects from a prior with a different mixture weight, call it
Π, to explore robustness to the choice of prior. In both cases we average across a collection
12
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of values of w’s.

Figure 2: π = Π: comparison between the optimal design and the Bayesian Adaptive Randomization (BAR). Each curve plots the difference in the expected trial utility,
˜ − U(dBAR ). Patient horizon Nh = 1000, trial size N = 50.
U(d)
In order to facilitate the display of the results graphically, we assumed that Π1 = Π2 = Π
and π1 = π2 = π. Figure 2 shows the comparison between the optimal design and BAR
when generating from the design prior. The first panel shows how the difference in expected
trial utility changes with π by holding P r(b = 1) constant. The second panel illustrates the
˜ − U(dBAR ) and P r(b = 1) with fixed π. For each combination
relationship between U(d)
of π and P r(b = 1), the two designs are used to implement trials with the same simulated
patients, we then observe the numbers of favorable treatment outcomes for the two designs
and compute the difference. Each curve in the two panels of Figure 2 is the expected utility
lost by using BAR compared to the best achievable result. The difference between BAR and
the theoretical optimum is generally small, between 2.5% and 4% of the size of the patient
horizon.
In the first panel, the difference between the optimal design and BAR is minimized
when the patient horizon consists of identical patients, namely, either all patients have
the biomarker mutation or none has. The difference in expected utility increases when
the subgroups are becoming more balanced and the maximum is achieved when the two
13
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subgroups are of equal size. At a fixed biomarker prevalence, the largest difference in expected
utility is observed when the prior expects most difference in the treatment efficacy in patient
subgroups (π = 0). When the subgroups are more closely related, that is, when the biomarker
status is expected to play a less important role in predicting patients’ responses to treatments,
the difference between the two trial designs is smaller. The difference between BAR and the
theoretical optimum is increasing with diminishing π.
The second panel plots the relationship between the difference in expected utility and the
˜ − U(dBAR )
prevalence of mutations. With fixed π and as P r(b = 1) is more balanced, U(d)
increases when the expected trial utility of both the optimal design and BAR decreases.

3.3

The Bayesian Adaptive Randomization and the Play the Winner Rule

There has been a growing interest in comparing Bayesian and frequentist adaptive designs.
The ”play-the-winner”(PW) rule [Zelen, 1969, Wei and Durham, 1978] has been used in
designing several clinical trials [Bartlett et al., 1985, Tamura et al., 1994, Yao and Wei,
1996].In this section, we compare the BAR to the PW in terms of the expected trial utility.
Our goal here is to quantify, from a Bayesian standpoint, the change in utility associated
with using a practical approach such as PW as compared to the BAR.
Each curve in Figure 3 plots the difference in expected trial utility U(dBAR ) − U(dP W ).
The three panels show the scenarios where treatment effects are generated from priors with
different mixture weights (Π). Depending on the scenario chosen, PW can have a worse
or better utility than BAR, though BAR achieves a higher utility in the vast majority of
cases combined. The difference can be large, as many as 50 additional successfully treated
patients out of a patient horizon of size 1000. The difference in expected utility decreases
when the subgroups become more balanced. When the subgroups are highly imbalanced,
the difference is relatively robust to the choice of π. PW has better utility when the prior
rules out a biomarker effect when there is in fact a strong one, and when the subgroups are
14
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Figure 3: At different combinations of Π × π: comparison between U(dBAR ) and U(dP W ).
Patient horizon Nh = 1000, trial size N = 50
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relatively balanced.

4

Discussion

In this article, we derive a theoretical optimal adaptive design, where treatment assignment
is allowed to depend on a binary biomarker. The optimal design, maximizes the expected
trial utility given by the expected number of favorable outcomes with a given patient horizon.
When treatment efficacy depends on biomarkers, our analysis shows how this relationship
affects the best achievable results in terms of the expected trial utility in trials where treatment assignments are adaptive on early treatment outcomes. Our work provides absolute
benchmark for the evaluation of trial designs in personalized medicine.
Our analysis is the first to consider optimal designs when treatment efficacy depends on
biomarkers. We hope it will provide the basis to consider more complex situations as well.
Although here we focus on maximizing the number of favorable outcomes, our approach can
be easily modified to handle other utility functions.
The optimal design is an application of dynamic programming, which records every possible outcome path when conducting a trial. This feature of the algorithm imposes heavy
computational burden, even for a modest trial size. In this context we wrote simulation programs that reduce the dimension of the data structure and free up machine memory during
the implementation of trials. However, computational demands remain a challenge for this
type of approach.
In practice it is uncommon to implement trials when the treatment assignment is deterministic for each patient. To address this concern, we also consider an adaptive design where
the treatment assignment is randomized. By definition, the largest utility gain is achieved
when the treatment assignment is optimal and deterministic, but our work allows one to
benchmark a proposed suboptimal randomized design against the optimum. Our comparison between the optimal design and other designs quantifies the difference in expected trial
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utility under different scenarios. When the number of patients to be cured is of primary
concern, the optimal design may be preferable. There could also be situations where a small
portion of the expected trial utility is sacrificed for a design that has easier interpretation or
includes a randomized treatment assignment.
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